[Pharmacokinetics of intravenous rifampicin (RMP) and its clinical evaluation in purulent bacterial meningitis]. 1981

F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli

A combined kinetic and clinical study showed that rifampicin displays good tissue diffusibility, though it may have a tendency to accumulate. A liquor transfer sufficient for the bacteria most commonly responsible for meningeal inflammation was observed; 15/18 cases of purulent bacterial meningitis treated were clinically cured without sequelae, while 1 displayed considerable improvement. Two patients died from unforseen, uncontrollable complications that were not related to administration of the drug.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
September 1984, The Journal of antimicrobial chemotherapy,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
May 1968, Giornale di malattie infettive e parassitarie,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
May 1968, Giornale di malattie infettive e parassitarie,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
February 1962, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
January 1979, Acquisitions medicales recentes,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
January 2013, The Lancet. Infectious diseases,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
January 1985, Journal of neurology,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
April 1988, The Japanese journal of antibiotics,
F Di Nola, and M Eandi, and M L Soranzo, and E Capra, and G Bosio, and C Bramato, and B Salassa, and L Bendiscioli
October 2006, Therapeutic drug monitoring,
Copied contents to your clipboard!